Commonwealth Equity Services, LLC Biovie Inc. Transaction History

Commonwealth Equity Services, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	BUY	$2.75 - $5.17 $1,375 - $2,585	500 Added 2.96%	17,370 $59,000
Q2 2023 Aug 10, 2023	BUY	$4.09 - $8.29 $2,515 - $5,098	615 Added 3.78%	16,870 $73,000
Q1 2023 May 11, 2023	BUY	$4.89 - $10.53 $19,951 - $42,962	4,080 Added 33.51%	16,255 $131,000
Q4 2022 Feb 07, 2023	BUY	$3.86 - $42.0 $46,995 - $511,350	12,175 New	12,175 $94,000

4.73M

17.2K

27K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $83.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.